Developer docs
API playgroundTry for free, no card

Search company profiles

The Pfizer Foundation

Full company profile

uuid0006cva

Namestring
The Pfizer Foundation
Legal namestring
Pfizer Inc.
Websiteurl
pfizer.com
Company typeenum
Public
Founded yearint
1849
Descriptiontext

The Pfizer Foundation is the charitable organization established by Pfizer Inc., focused on advancing global health equity and patient access to medicines. The Foundation's programmatic footprint spans three primary pillars: (1) the Pfizer RxPathways patient assistance program, which has operated for over 25 years providing insurance counseling, co-pay assistance, and free or discounted medicines to millions of uninsured and underinsured US patients; (2) the Accord for a Healthier World initiative, launched in 2022-05, which delivers Pfizer's full portfolio of medicines and vaccines on a not-for-profit basis to 1.2 billion people across 45 lower-income countries through partnerships with governments and global health organizations; and (3) the Global Health Fellows program, deploying skills-based volunteering and capacity-building partnerships with organizations including PharmAccess (Ghana, Tanzania), North Star Alliance (Kenya), Health Builders (Rwanda), Save the Children, the Infectious Diseases Institute (Uganda), IFPW Foundation, and The Leo Project, with the STEP 2.0 supply-chain training program spanning India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia.

The Foundation leverages Pfizer Inc.'s biopharmaceutical infrastructure — headquartered at 66 Hudson Boulevard East, New York, with 10,000+ employees and 1,500 R&D scientists supporting a 96-candidate pipeline (35 Phase 1, 25 Phase 2, 31 Phase 3, 5 Registration) across Oncology, Inflammation & Immunology, Internal Medicine, and Vaccines. Marketed products made available through Foundation programs include IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), HYMPAVZI (marstacimab), ELREXFIO (elranatamab-bcmm), LITFULO (ritlecitinib), NURTEC (rimegepant), TALZENNA (talazoparib), XTANDI (enzalutamide), and ABRYSVO (RSV vaccine). The Foundation also funds cancer-equity initiatives, including the Change the Odds partnership with the American Cancer Society, the SPARC MBC Challenge with UICC ($760,000 in grants to 20 organizations across 18 countries), and grants to Susan G. Komen and the Avon Foundation.

As a charitable entity (private, non-publicly traded), the Foundation operates on grant inflows rather than product revenue. Its leadership includes Caroline Roan, Vice President of Corporate Responsibility and President of the Pfizer Foundation. The Foundation's strategic role is to extend the reach of Pfizer Inc.'s commercial pharmaceutical portfolio into underserved populations, complementing the parent's commercial revenue model (pharmaceutical product sales distributed via field sales, PfizerPro for healthcare professionals, PfizerForAll for consumers, and a global distributor network). Note: significant data in this dossier pertains to Pfizer Inc. rather than the Foundation directly; the Foundation's own financials, headcount, and operational metrics are not separately disclosed in the provided sources.

Short descriptiontext

The Pfizer Foundation is the charitable arm of Pfizer Inc., advancing global health equity through the 25+ year Pfizer RxPathways patient assistance program, the Accord for a Healthier World initiative serving 1.2 billion people across 45 lower-income countries, and Global Health Fellows partnerships across Africa and Asia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
global health equity programs, health-focused philanthropy, patient advocacy grants, corporate charitable foundation, capacity building partnerships
Industry3 codes
1International Grantmaking & Development Foundations
CodeBPAGAKAHPrimaryYes
2Medical Missions & Global Health NGOs
CodeBPAGACAIPrimaryNo
3Health & Medical Research Grantmaking Foundations
CodeBPAGAKALPrimaryNo
NAICS code3 codes
  • Grantmaking Foundations813211
  • Grantmaking and Giving Services81321
  • Voluntary Health Organizations813212
Product category
Corporate Philanthropy & Health Grants
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pfizer generates revenue through the sale of prescription pharmaceutical products and vaccines. Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.

pfizer.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Others, Personnel, Marketing or Sales, Operations
Pricing details1 tier
1Pfizer RxPathways patient assistance program
ModelOtherBilling cadenceOther
Notes

Connects eligible patients to assistance programs offering insurance support, co-pay help, and medicines for free or at savings.

pfizer.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

The Pfizer Foundation is a corporate charitable organization that funds and operates global health equity programs, multi-year grant initiatives, and skills-based volunteering deployments (Global Health Fellows) in partnership with NGOs, patient advocacy organizations, and ministries of health across multiple countries. Its portfolio spans cancer disparities funding, patient advocacy grants, infectious disease capacity building, and supply chain training in lower-income countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.
+2 more records
Product overview1 text field

Pfizer is a biopharmaceutical company that discovers, develops, and commercializes medicines and vaccines across four key therapeutic areas: Inflammation & Immunology, Internal Medicine (including cardiovascular and metabolic diseases), Oncology, and Vaccines. The company's product portfolio consists of marketed products (including IBRANCE, PADCEV, TUKYSA, HYMPAVZI, ELREXFIO, LITFULO, NURTEC, TALZENNA, XTANDI, and ABRYSVO) and a robust pipeline of investigational candidates in various phases of clinical development. Pfizer also operates patient support programs (Pfizer RxPathways) and digital platforms (PfizerForAll for patients, PfizerPro for healthcare professionals) to support access to medicines and health information.

Product and service6 records
1Global Health Fellows Program
CategoryGlobal Health Capacity Building
Description

Skills-based volunteering program that places Pfizer employees with partner NGOs and health systems in lower-income countries to support public health insurance implementation, mobile health service delivery, health workforce training, data visualization, and infectious disease capacity building. Partners include PharmAccess, North Star Alliance, Health Builders, Save the Children, Infectious Diseases Institute, and The Leo Project.

2Change the Odds Initiative
CategoryCancer Disparities Grant Program
Description

Three-year initiative co-funded with the American Cancer Society to address cancer disparities and improve health outcomes in medically underrepresented US communities. The program sits at the intersection of Foundation grantmaking and Pfizer's oncology equity agenda.

3SPARC MBC Challenge
CategoryPatient Advocacy Grant Program
Description

Grant program with the Union for International Cancer Control (UICC) that funds organizations addressing metastatic breast cancer. The Challenge awarded $760,000 in grants to 20 organizations from 18 countries, supporting a previously underserved population in cancer advocacy funding.

4Komen Disparities Support Program
CategoryCancer Disparities Grant Program
Description

Grant-funded program with Susan G. Komen to reduce disparities in breast cancer outcomes between African-American and Caucasian women in the United States through targeted support of the Komen Disparities initiative.

5STEP 2.0 Supply Chain Training Program
CategoryPharmaceutical Supply Chain Capacity Building
Description

Supply chain training program delivered with IFPW Foundation that coaches healthcare supply chain professionals across India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia. Designed to strengthen pharmaceutical distribution and medicine availability capability in emerging markets.

6Patient Access Sponsorship (Pfizer RxPathways Foundation Support)
CategoryPatient Assistance Program
Description

Foundational philanthropic support for Pfizer's RxPathways patient assistance platform. Provides insurance counseling, co-pay help, and free or discounted medicines to millions of eligible uninsured and underinsured patients, operating for 25+ years.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Collaboration on COVID-19 vaccine development and distribution. Pfizer and BioNTech co-developed the Pfizer-BioNTech COVID-19 Vaccine using mRNA technology. The partnership continues with COVID-19 vaccine development for children (6 months through 11 years of age).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Co-development agreement for PADCEV (enfortumab vedotin) for muscle-invasive bladder cancer (EV-303, EV-304 studies).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Co-development of Lyme Disease Vaccine Candidate (PF-07307405) through the VALOR clinical trial program.

4Accord for a Healthier World Partners (45 Lower-Income Countries)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

Pfizer is working with governments, the global health community, and others who share commitment to advancing health equity. Offering full portfolio of medicines and vaccines for which Pfizer has global rights on a not-for-profit basis to 1.2 billion people in 45 lower-income countries.

pfizer.com
Strategic tierMajorTypeGTM or Marketing Partner
Description

Pfizer supports organizations focusing on prescription access and provides grants to fund essential programs and services for patients coping with various cancers. In 2014, donated $6.3 million to US co-pay foundations for life-saving cancer medicines.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global Health Fellows partnership with PharmAccess in Ghana and Tanzania to support implementation of public health insurance programs and health equity funds to reach at-risk populations.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global Health Fellows partnership in Kenya to improve healthcare access through mobile health services for mobile and migrant populations.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global Health Fellows partnership in Rwanda to strengthen health systems through training and capacity building.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global Health Fellows partnership to improve child health outcomes through skills-based volunteering and capacity building.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global Health Fellows partnership in Uganda to strengthen infectious disease treatment and research capacity.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Partnership through Strategic Training Executive Program (STEP 2.0) to provide coaching to supply chain healthcare professionals in India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Global Health Fellows partnership in Kenya supporting a community-based organization through data visualization training and dashboard creation for tracking performance indicators.

13Change the Odds: American Cancer Society and Pfizer
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Three-year initiative aimed at addressing cancer disparities and improving health outcomes in medically underrepresented communities across the United States.

pfizer.com
14Union for International Cancer Control (UICC)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

First-of-its-kind initiative to address unique challenges facing metastatic breast cancer patients. SPARC MBC Challenge awarded $760,000 in grants to 20 organizations from 18 countries.

pfizer.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Supported Komen Disparities initiative to reduce difference in breast cancer outcomes between African-American and Caucasian women in the US.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Grants program supporting people living with metastatic breast cancer. In 2015, Avon and Pfizer each contributed $500,000 in grants awarded to 23 nonprofit organizations.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Chronic Myeloid Leukemia (CML) Patient Experience Registry to identify and understand psychosocial and emotional needs of CML patients.

18ASCO/Conquer Cancer Foundation
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Supported CancerLinQ initiative, a health information technology platform designed to improve quality and value of cancer care.

pfizer.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Corporate foundation of a major global biopharma, focused on health equity and serious disease grantmaking. Operates disease-focused programs (cancer, cardiovascular, immunology) in underserved populations — directly comparable in scope, structure, and mission to the Pfizer Foundation.

TypeDirect peer
Description

Corporate foundation of a top-3 global pharma/medtech company. Runs global health workforce, patient access, and frontline health worker programs internationally — the closest peer in scale and global health footprint.

TypeDirect peer
Description

The philanthropic arm of Merck & Co., focused on health equity, cancer, infectious disease, and health workforce capacity-building in lower-income countries. Operates Global Health Fellows-like programs and aligns closely with Pfizer Foundation's model.

TypeDirect peer
Description

Corporate foundation of Eli Lilly, focused on diabetes/obesity, oncology, and health equity. Comparable mid-to-large biopharma corporate foundation with patient access and disease-state grantmaking.

TypeDirect peer
Description

Foundation of Novartis focused on reimagining healthcare delivery in low- and middle-income countries through innovative programs (e.g., chronic disease management). Direct peer in international health equity grantmaking.

TypeDirect peer
Description

Corporate foundation of GSK focused on global health, vaccines access, and health system strengthening in lower-income countries. Highly comparable in mission, scale, and partnership model.

TypeDirect peer
Description

Corporate foundation of Roche focused on health equity, oncology access, and health systems in lower-income countries. Comparable in oncology-heavy grantmaking and global health footprint.

TypeDirect peer
Description

Corporate foundation of Sanofi with international health equity programs, patient assistance, and capacity-building initiatives. Mid-tier biopharma corporate foundation comparable to the Pfizer Foundation in scope.

TypeDirect peer
Description

Corporate foundation of AbbVie with patient assistance and health equity programs focused on oncology, immunology, and neuroscience. Direct peer in pharma corporate giving structure.

TypeBroad incumbent
Description

The world's largest health-focused philanthropy with a $70B+ endowment and deep focus on global health equity, vaccine access, and infectious disease in lower-income countries. Operates at a much larger scale than any corporate pharma foundation but addresses the same end beneficiaries.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The Pfizer Foundation

Corporate Philanthropy & Health Grantspfizer.com

The Pfizer Foundation is the charitable arm of Pfizer Inc., advancing global health equity through the 25+ year Pfizer RxPathways patient assistance program, the Accord for a Healthier World initiative serving 1.2 billion people across 45 lower-income countries, and Global Health Fellows partnerships across Africa and Asia.

What The Pfizer Foundation does

The Pfizer Foundation is the charitable organization established by Pfizer Inc., focused on advancing global health equity and patient access to medicines. The Foundation's programmatic footprint spans three primary pillars: (1) the Pfizer RxPathways patient assistance program, which has operated for over 25 years providing insurance counseling, co-pay assistance, and free or discounted medicines to millions of uninsured and underinsured US patients; (2) the Accord for a Healthier World initiative, launched in 2022-05, which delivers Pfizer's full portfolio of medicines and vaccines on a not-for-profit basis to 1.2 billion people across 45 lower-income countries through partnerships with governments and global health organizations; and (3) the Global Health Fellows program, deploying skills-based volunteering and capacity-building partnerships with organizations including PharmAccess (Ghana, Tanzania), North Star Alliance (Kenya), Health Builders (Rwanda), Save the Children, the Infectious Diseases Institute (Uganda), IFPW Foundation, and The Leo Project, with the STEP 2.0 supply-chain training program spanning India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia.

The Foundation leverages Pfizer Inc.'s biopharmaceutical infrastructure — headquartered at 66 Hudson Boulevard East, New York, with 10,000+ employees and 1,500 R&D scientists supporting a 96-candidate pipeline (35 Phase 1, 25 Phase 2, 31 Phase 3, 5 Registration) across Oncology, Inflammation & Immunology, Internal Medicine, and Vaccines. Marketed products made available through Foundation programs include IBRANCE (palbociclib), PADCEV (enfortumab vedotin), TUKYSA (tucatinib), HYMPAVZI (marstacimab), ELREXFIO (elranatamab-bcmm), LITFULO (ritlecitinib), NURTEC (rimegepant), TALZENNA (talazoparib), XTANDI (enzalutamide), and ABRYSVO (RSV vaccine). The Foundation also funds cancer-equity initiatives, including the Change the Odds partnership with the American Cancer Society, the SPARC MBC Challenge with UICC ($760,000 in grants to 20 organizations across 18 countries), and grants to Susan G. Komen and the Avon Foundation.

As a charitable entity (private, non-publicly traded), the Foundation operates on grant inflows rather than product revenue. Its leadership includes Caroline Roan, Vice President of Corporate Responsibility and President of the Pfizer Foundation. The Foundation's strategic role is to extend the reach of Pfizer Inc.'s commercial pharmaceutical portfolio into underserved populations, complementing the parent's commercial revenue model (pharmaceutical product sales distributed via field sales, PfizerPro for healthcare professionals, PfizerForAll for consumers, and a global distributor network). Note: significant data in this dossier pertains to Pfizer Inc. rather than the Foundation directly; the Foundation's own financials, headcount, and operational metrics are not separately disclosed in the provided sources.

The Pfizer Foundation firmographics

Firmographics
Name
The Pfizer Foundation
Legal name
Pfizer Inc.
Website
https://pfizer.com
Company type
Public
Founded year
1849
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
The Pfizer Foundation is the charitable arm of Pfizer Inc., advancing global health equity through the 25+ year Pfizer RxPathways patient assistance program, the Accord for a Healthier World initiative serving 1.2 billion people across 45 lower-income countries, and Global Health Fellows partnerships across Africa and Asia.
Ownership category
akta.pro rank

The Pfizer Foundation industry classification

Industry
Product category
Corporate Philanthropy & Health Grants
NAICS
Grantmaking Foundations (813211), Grantmaking and Giving Services (81321), Voluntary Health Organizations (813212)
akta.pro primary industry
International Grantmaking & Development Foundations (BPAGAKAH)
akta.pro secondary industries
Medical Missions & Global Health NGOs (BPAGACAI), Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

  • Global health equity programs
  • Health-focused philanthropy
  • Patient advocacy grants
  • Corporate charitable foundation
  • Capacity building partnerships

Where The Pfizer Foundation is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

The Pfizer Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Others, Personnel, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Pfizer generates revenue through the sale of prescription pharmaceutical products and vaccines. Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.

Pricing tiers

ModelBillingPrice
OtherOtherPfizer RxPathways patient assistance program

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

The Pfizer Foundation product offering

Product offering

Core offering

The Pfizer Foundation is a corporate charitable organization that funds and operates global health equity programs, multi-year grant initiatives, and skills-based volunteering deployments (Global Health Fellows) in partnership with NGOs, patient advocacy organizations, and ministries of health across multiple countries. Its portfolio spans cancer disparities funding, patient advocacy grants, infectious disease capacity building, and supply chain training in lower-income countries.

Product overview

Pfizer is a biopharmaceutical company that discovers, develops, and commercializes medicines and vaccines across four key therapeutic areas: Inflammation & Immunology, Internal Medicine (including cardiovascular and metabolic diseases), Oncology, and Vaccines. The company's product portfolio consists of marketed products (including IBRANCE, PADCEV, TUKYSA, HYMPAVZI, ELREXFIO, LITFULO, NURTEC, TALZENNA, XTANDI, and ABRYSVO) and a robust pipeline of investigational candidates in various phases of clinical development. Pfizer also operates patient support programs (Pfizer RxPathways) and digital platforms (PfizerForAll for patients, PfizerPro for healthcare professionals) to support access to medicines and health information.

Differentiator

Problem solved

Functional benefit

Products and services

  • Global Health Fellows Program Skills-based volunteering program that places Pfizer employees with partner NGOs and health systems in lower-income countries to support public health insurance implementation, mobile health service delivery, health workforce training, data visualization, and infectious disease capacity building. Partners include PharmAccess, North Star Alliance, Health Builders, Save the Children, Infectious Diseases Institute, and The Leo Project.
  • Change the Odds Initiative Three-year initiative co-funded with the American Cancer Society to address cancer disparities and improve health outcomes in medically underrepresented US communities. The program sits at the intersection of Foundation grantmaking and Pfizer's oncology equity agenda.
  • SPARC MBC Challenge Grant program with the Union for International Cancer Control (UICC) that funds organizations addressing metastatic breast cancer. The Challenge awarded $760,000 in grants to 20 organizations from 18 countries, supporting a previously underserved population in cancer advocacy funding.
  • Komen Disparities Support Program Grant-funded program with Susan G. Komen to reduce disparities in breast cancer outcomes between African-American and Caucasian women in the United States through targeted support of the Komen Disparities initiative.
  • STEP 2.0 Supply Chain Training Program Supply chain training program delivered with IFPW Foundation that coaches healthcare supply chain professionals across India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia. Designed to strengthen pharmaceutical distribution and medicine availability capability in emerging markets.
  • Patient Access Sponsorship (Pfizer RxPathways Foundation Support) Foundational philanthropic support for Pfizer's RxPathways patient assistance platform. Provides insurance counseling, co-pay help, and free or discounted medicines to millions of eligible uninsured and underinsured patients, operating for 25+ years.

Quantifiable outcome

  • Every product is the result of 1,500 scientists overseeing more than 500,000 lab tests and over 36 clinical trials before the first prescription.
  • +2 more outcomes

Companies that use The Pfizer Foundation

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles4 records

The Pfizer Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

The Pfizer Foundation partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core, major and minor.

  • BioNTechcoreStrategic or Co-development Partner · 1 May 2026Collaboration on COVID-19 vaccine development and distribution. Pfizer and BioNTech co-developed the Pfizer-BioNTech COVID-19 Vaccine using mRNA technology. The partnership continues with COVID-19 vaccine development for children (6 months through 11 years of age).
  • Astellas PharmacoreStrategic or Co-development Partner · 1 May 2026Co-development agreement for PADCEV (enfortumab vedotin) for muscle-invasive bladder cancer (EV-303, EV-304 studies).
  • ValnevacoreStrategic or Co-development Partner · 1 January 2026Co-development of Lyme Disease Vaccine Candidate (PF-07307405) through the VALOR clinical trial program.
  • Accord for a Healthier World Partners (45 Lower-Income Countries)coreStrategic or Co-development Partner · 1 May 2022Pfizer is working with governments, the global health community, and others who share commitment to advancing health equity. Offering full portfolio of medicines and vaccines for which Pfizer has global rights on a not-for-profit basis to 1.2 billion people in 45 lower-income countries.
  • Patient Advocacy OrganizationsmajorGTM or Marketing PartnerPfizer supports organizations focusing on prescription access and provides grants to fund essential programs and services for patients coping with various cancers. In 2014, donated $6.3 million to US co-pay foundations for life-saving cancer medicines.
  • PharmAccessmajorStrategic or Co-development PartnerGlobal Health Fellows partnership with PharmAccess in Ghana and Tanzania to support implementation of public health insurance programs and health equity funds to reach at-risk populations.
  • North Star AlliancemajorStrategic or Co-development PartnerGlobal Health Fellows partnership in Kenya to improve healthcare access through mobile health services for mobile and migrant populations.
  • Health BuildersmajorStrategic or Co-development PartnerGlobal Health Fellows partnership in Rwanda to strengthen health systems through training and capacity building.
  • Save the ChildrenmajorStrategic or Co-development PartnerGlobal Health Fellows partnership to improve child health outcomes through skills-based volunteering and capacity building.
  • Infectious Diseases Institute (Uganda)majorStrategic or Co-development PartnerGlobal Health Fellows partnership in Uganda to strengthen infectious disease treatment and research capacity.
  • IFPW FoundationmajorStrategic or Co-development PartnerPartnership through Strategic Training Executive Program (STEP 2.0) to provide coaching to supply chain healthcare professionals in India, Djibouti, Ethiopia, Kenya, Nigeria, Rwanda, Pakistan, and Southeast Asia.
  • The Leo ProjectmajorStrategic or Co-development PartnerGlobal Health Fellows partnership in Kenya supporting a community-based organization through data visualization training and dashboard creation for tracking performance indicators.
  • Change the Odds: American Cancer Society and PfizermajorStrategic or Co-development PartnerThree-year initiative aimed at addressing cancer disparities and improving health outcomes in medically underrepresented communities across the United States.
  • Union for International Cancer Control (UICC)majorStrategic or Co-development PartnerFirst-of-its-kind initiative to address unique challenges facing metastatic breast cancer patients. SPARC MBC Challenge awarded $760,000 in grants to 20 organizations from 18 countries.
  • Susan G. KomenminorGTM or Marketing PartnerSupported Komen Disparities initiative to reduce difference in breast cancer outcomes between African-American and Caucasian women in the US.
  • AVON Foundation for WomenminorGTM or Marketing PartnerGrants program supporting people living with metastatic breast cancer. In 2015, Avon and Pfizer each contributed $500,000 in grants awarded to 23 nonprofit organizations.
  • Cancer Support Community / The Leukemia & Lymphoma SocietyminorStrategic or Co-development PartnerCollaboration with Chronic Myeloid Leukemia (CML) Patient Experience Registry to identify and understand psychosocial and emotional needs of CML patients.
  • ASCO/Conquer Cancer FoundationminorStrategic or Co-development PartnerSupported CancerLinQ initiative, a health information technology platform designed to improve quality and value of cancer care.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

The Pfizer Foundation competitors and assessment

Company assessment

Direct peers

  • Bristol Myers Squibb Foundation: Corporate foundation of a major global biopharma, focused on health equity and serious disease grantmaking. Operates disease-focused programs (cancer, cardiovascular, immunology) in underserved populations — directly comparable in scope, structure, and mission to the Pfizer Foundation.
  • Johnson & Johnson Foundation: Corporate foundation of a top-3 global pharma/medtech company. Runs global health workforce, patient access, and frontline health worker programs internationally — the closest peer in scale and global health footprint.
  • Merck Foundation: The philanthropic arm of Merck & Co., focused on health equity, cancer, infectious disease, and health workforce capacity-building in lower-income countries. Operates Global Health Fellows-like programs and aligns closely with Pfizer Foundation's model.
  • Eli Lilly Foundation: Corporate foundation of Eli Lilly, focused on diabetes/obesity, oncology, and health equity. Comparable mid-to-large biopharma corporate foundation with patient access and disease-state grantmaking.
  • Novartis Foundation: Foundation of Novartis focused on reimagining healthcare delivery in low- and middle-income countries through innovative programs (e.g., chronic disease management). Direct peer in international health equity grantmaking.
  • GSK Foundation: Corporate foundation of GSK focused on global health, vaccines access, and health system strengthening in lower-income countries. Highly comparable in mission, scale, and partnership model.
  • Roche Foundation: Corporate foundation of Roche focused on health equity, oncology access, and health systems in lower-income countries. Comparable in oncology-heavy grantmaking and global health footprint.
  • Sanofi Foundation: Corporate foundation of Sanofi with international health equity programs, patient assistance, and capacity-building initiatives. Mid-tier biopharma corporate foundation comparable to the Pfizer Foundation in scope.
  • AbbVie Foundation: Corporate foundation of AbbVie with patient assistance and health equity programs focused on oncology, immunology, and neuroscience. Direct peer in pharma corporate giving structure.

Broad incumbents

  • Bill & Melinda Gates Foundation: The world's largest health-focused philanthropy with a $70B+ endowment and deep focus on global health equity, vaccine access, and infectious disease in lower-income countries. Operates at a much larger scale than any corporate pharma foundation but addresses the same end beneficiaries.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

The Pfizer Foundation social profiles

Digital presence

The Pfizer Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The Pfizer Foundation leadership team

Management profile

Number of profiles

Profiles1 record

The Pfizer Foundation subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

The Pfizer Foundation funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The Pfizer Foundation M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Pfizer Foundation

What does The Pfizer Foundation do?

The Pfizer Foundation is a corporate charitable organization that funds and operates global health equity programs, multi-year grant initiatives, and skills-based volunteering deployments (Global Health Fellows) in partnership with NGOs, patient advocacy organizations, and ministries of health across multiple countries. Its portfolio spans cancer disparities funding, patient advocacy grants, infectious disease capacity building, and supply chain training in lower-income countries.

Is The Pfizer Foundation a public or private company?

The Pfizer Foundation is a public company. It is classified as corporate owned and is currently operating.

When was The Pfizer Foundation founded?

The Pfizer Foundation was founded in 1849. It employs 5,001 to 10,000 people.

Where is The Pfizer Foundation based?

The Pfizer Foundation is headquartered in New York, United States, in the North America region.

How does The Pfizer Foundation make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are The Pfizer Foundation's main competitors?

Direct peers on record are Bristol Myers Squibb Foundation, Johnson & Johnson Foundation, Merck Foundation, Eli Lilly Foundation, Novartis Foundation, GSK Foundation, Roche Foundation, Sanofi Foundation and AbbVie Foundation. Bill & Melinda Gates Foundation is listed as a broad incumbent.

Does The Pfizer Foundation have an API?

No public API is recorded for The Pfizer Foundation.

What industry is The Pfizer Foundation in?

The Pfizer Foundation's product category is Corporate Philanthropy & Health Grants. Its primary akta.pro industry code is BPAGAKAH, International Grantmaking & Development Foundations, with a secondary code of BPAGACAI, Medical Missions & Global Health NGOs. Its NAICS code is 813211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Direct ReliefFrom Selma to the Bronx: How Local Health Centers Built Trust to Reach PatientsThe Rural Health Medical Program in Selma, Alabama, and Urban Health Plan in the Bronx, New York, presented their strategies for building patient trust and improving health access at a recent conference. These organizations were recipients of the Pfizer Foundation Innovation Awards in Community Health, which is administered by Direct Relief and has funded over 46 safety-net providers to reach millions of people with vaccinations and healthcare services.Direct ReliefDirect Relief and the Pfizer Foundation Announce New Grantees in Fifth Year of Infectious Disease ProgramDirect Relief and The Pfizer Foundation announced the third cohort of their Innovation Awards in Community Health, allocating $4.5 million over two years to 16 U.S. safety-net organizations. This initiative aims to expand access to infectious disease prevention, education, screening, and treatment across 11 states, building on a program that has previously reached over 1.3 million people.Direct ReliefA High Desert City Finds Innovative Solutions to HomelessnessThe City of Victorville has partnered with the nonprofit Symba Center and received support from the Pfizer Foundation and Direct Relief to address rising homelessness through an integrated medical, mental health, and housing model. This collaboration led to the opening of the Wellness Center in December 2023, which provides 110 non-congregate housing units alongside on-site medical and support services. The initiative aims to serve as a replicable model for other communities facing similar challenges with housing insecurity and resource limitations.Empresas de Capital Riesgo en EspaBioPatch wins Innomakers4Health, the innovation program by Wayra, Pfizer, and the Pfizer Foundation that promotes entrepreneurship in healthcareBioPatch won the seventh edition of Innomakers4Health, an innovation program organized by Wayra, Pfizer, and the Pfizer Foundation, held this past weekend in Madrid. BioPatch won the 'Early Innovators' category for developing a non-invasive patch that detects breast cancer by measuring the electrical conductivity of cancerous cells. As prize, BioPatch received €3,000 and will accelerate its project at InnomakersLAB with access to a six-month mentorship program and workspace at Wayra's Madrid offices.Vanguard NewsPfizer Foundation donates $6.4m to combat diseases in West AfricaThe Pfizer Foundation announced a $6.4 million donation to support programs combating infectious diseases in Nigeria and Ghana through grants to CARE, the International Rescue Committee, and PATH. The funding aims to reduce childhood mortality, improve maternal health, and address antimicrobial resistance in these West African nations.PR NewswireVital Support for Zika Response Provided by Pfizer and Pfizer Foundation ContributionsThe CDC Foundation announced a $1 million donation from the Pfizer Foundation along with in-kind donations of up to 170,000 doses of injectable reversible contraceptive product from Pfizer to support the Zika outbreak response. The contributions are directed toward the Zika Contraception Access Network program operating in Puerto Rico, which provides women with free reversible contraceptive methods to help avoid Zika-related pregnancy complications. Pfizer and the CDC Foundation framed the partnership as a collaborative effort to combat the growing health threat affecting families in affected areas.